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In this issue of Korean Circulation Journal, Ko et al.
1) report on 
the effectiveness and safety of percutaneous implantation of pul-
monary arterial stents in congenital heart disease between 1999 
and 2010 in one institute. Since Dr. Mullins recognized the poten-
tial for stents to treat pulmonary arterial stenosis effectively which 
were compared to the surgical methods, many reports about these 
experiences have been reported. Most of the studies demonstrated 
the effectiveness of pulmonary arterial stenting by increasing pul-
monary artery size, reducing pressure gradients, decreasing right 
ventricular pressure and improving the disparity in pulmonary ar-
terial blood flow.
2-5) However, there are few reports with long-term 
follow-up data in a large population of patients, especially no mul-
ticenter, randomized controlled studies as Ko et al.
1) noted. There-
fore, in spite of the efforts of many doctors, the use of stents to tr-
eat pulmonary arterial stenosis is still considered “off label”-i.e., not 
approved by the Food and Drug Administration, even though the 
investigational device exemption (IDE) was obtained by Dr. Mullins’ 
efforts. Recently, Law et al.
6) reported a long-term follow-up study 
including Dr. Mullins’ very first human implantation of stents in the 
pulmonary artery. They confirmed that intravascular stents maintain-
ed their safety and efficacy over 15-20 years in relieving branch pul-
monary artery stenosis. However, the follow-up of this study also 
has limitations, that is, 18 of 68 patients were lost to follow-up less 
than 5 years after stent implantation. 
Current issues in pulmonary arterial stent implantation includ-
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ing jailed side branches, redilation of the stent, stenting at early age 
such as infancy and stent fracture. In Law’s study,
6) 27 of 55 stents 
(49%) resulted in partial or complete jailing of a side branch. Only 
5/27 (19%) of the jailed vessels had complete occlusion of the jailed 
side branch and the group of patients with a compromised side br-
anch flow still had a sustained reduction in right ventricular pres-
sure; thus, jailing of a side branch may be acceptable if the gain is gr-
eater than the loss of flow to the jailed vessel. Nevertheless, we sh-
ould try to use an open-cell stent such as the Mega LD or Maxi LD 
(EV3, Plymouth, MN, USA) in case of unavoidable jailing side branch-
es. Regarding further stent dilation or additional stent implantation, 
several studies
6-8) confirmed its safety and effectiveness, and Staple-
ton et al.
7) found that patients who had their initial stents placed be-
fore age 10 years had an increased risk of needing further interven-
tions at subsequent catheterizations. Initial vessel diameter or per-
cent change in vessel diameter post stent were not associated with 
increased risk for repeat interventions. Stanfill et al.
9) showed that 
stent implantation in infants was safe and effective, and serial redil-
ation was also possible. However, they emphasized that efforts 
should be made to implant large stents with adult diameter poten-
tial in children who will not require further cardiac surgery and small- 
or medium-sized stents in carefully selected infants who will ultima-
tely require future cardiac surgery. Stent fracture is rare and asymp-
tomatic in pulmonary artery stenting, but frequently occurs in the 
right ventricle to pulmonary artery conduit stent, and it may cause 
conduit restenosis or stent fragment embolization. Although fluo-
roscopy remains the gold standard to diagnose stent fractures, la-
teral projection chest radiographs may improve detection.
10) 
The study of Ko et al. showed us the effectiveness and safety of 
percutaneous implantation of the pulmonary artery stent in short 
term result as many previous reports have done. It is not a long term 
follow-up result, also not a randomized controlled study compared 
to a surgical treatment. Among the 42 patients, only 8 patients 
had follow-up angiography. The study did not cover the current is-
sues of pulmonary artery stent mentioned above. The authors wor-
ried about harmful vessel damage in using the Genesis stent (Cor-
dis, Warren, NJ), but this was not correct because the Genesis stent 9 Seong-Ho Kim
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can be introduced through an 8F sheath with a 14-16 mm balloon 
catheter. They implanted a stent in a 0.5 year-old infant, and we 
really want to know what the indication was, what kind of stent was 
used, what was the follow up result, etc. To add strength to this 
study, they should give us more detailed information about the com-
plicated cases, and then we would share their painful experiences 
and might avoid the same complications in our practices.
In conclusion, the effectiveness and safety of the pulmonary ar-
tery stent for pulmonary artery stenosis are definitely accepted in 
many centers caring for a large number of patients with congeni-
tal heart disease. However, its use is still considered “off label”. This 
means we should try to report on the detailed long term follow-up 
of patients who underwent pulmonary artery stent implantation to 
achieve an approval from the FDA.
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